Towards Optimizing Peptide-Based Inhibitors of Protein-Protein Interactions: Predictive Saturation Variation Scanning (PreSaVS) by Hetherington, K et al.
© 2021 The Author(s). Published by the Royal Society of Chemistry RSC Chem. Biol.
Cite this: DOI: 10.1039/d1cb00137j
Towards optimizing peptide-based inhibitors
of protein–protein interactions: predictive
saturation variation scanning (PreSaVS)†
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A simple-to-implement and experimentally validated computa-
tional workflow for sequence modification of peptide inhibitors of
protein–protein interactions (PPIs) is described.
Understanding and modulating PPIs is important both for
delineating molecular mechanisms of healthy cells and disease
states, and for directing drug discovery.1–3 However, PPIs are
challenging targets for molecular design.4 A significant propor-
tion of PPIs rely on short peptide motifs (SPMs)5 for affinity.
SPMs are often found in intrinsically disordered regions of
proteins6 and undergo disorder-to-order transitions to adopt
defined structures, e.g. a helices7 and b-strands,8 on interaction
with a target domain. The sequences of SPMs serve as powerful
templates for inhibitor design, and have motivated efforts to
develop peptide and peptidomimetic ligands,9,10 including
stapled11 and macrocyclic peptides,12 as potential therapeutics.
Strategies for peptide-based ligand development should explore
sequence space to maximise binding affinity whilst maintain-
ing good pharmacokinetic properties, such as solubility, cell
permeability, and resistance to proteolysis. Concerning affinity,
truncation and the identification of hot residues (i.e. side chains
that contribute significantly to the affinity of a PPI)13,14 through
alanine scanning15 represent practical approaches for obtaining
key information on the minimal determinants of binding. Enhanc-
ing affinity and/or selectivity through sequence variation is also
desirable as exemplified by alternative systematic experimental
sequence variation strategies, e.g. hydrophile scanning.16 How-
ever, generally, sequence space is too great too explore using
synthetic chemistry. Biological selection methods are powerful
and do allow more space to be searched,17–19 however, these
can be experimentally demanding and expensive. For all these
reasons, development and improvement of computational
approaches to examine and design PPIs are important.
Computational alanine scanning (CAS) is an important tool
within this armoury to speed up and direct experiments.20,21
Recent studies show the power of computational design;22,23
e.g., the use of Rosetta to identify helix bundles that selectively
modulate BCL-2 family interactions.23 Affinity mapped SORT-
CERY uses biological selection and deep sequencing to obtain
binding information and then develop computational models
of sequence-binding relationships to inform peptide design.24
Statistical data on tertiary structural motifs (TERMs) in the
RCSB Protein Data Bank (PDB) and the resulting TERM ener-
gies (dTERMen) have been used in design, predicting peptide
binding energies as accurately as structure-based tools, leading
to high-affinity peptide binders.25 However, these methods rely
on large data sets and/or multiple experimental designs being
pursued. Rosetta Backrub identifies tolerated sequences using
flexible backbone protein design. It uses a simulated annealing
and genetic algorithm optimization method to create a single
estimate for the tolerated sequence space.26–28 Finally, Alpha-
Space can be used to identify unoccupied spaces in PPIs, which
can be filled by natural or unnatural side chains in designs
targeting interfaces.29
Here, we describe a simple-to-implement and experimen-
tally validated computational workflow for sequence modifica-
tion of peptide-based PPI inhibitors. We call this in silico
Predictive Saturation Variation Scanning (PreSaVS). Rather
than knocking-out affinity (as in CAS), modifying a sequence
whilst retaining or even improving its potency is challenging: it
is unclear if further optimization of hot residues, or making
new interactions using non-hot residues30 is the best approach
and to what extent affinity can be increased. PreSaVS compu-
tationally substitutes each residue in a peptide sequence of
a Astbury Centre for Structural Molecular Biology, University of Leeds,
Woodhouse Lane, Leeds LS2 9JT, UK. E-mail: a.j.wilson@leeds.ac.uk
b School of Chemistry, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK
c School of Biochemistry, University of Bristol, Medical Sciences Building,
University Walk, Bristol BS8 1TD, UK. E-mail: r.sessions@bristol.ac.uk
d School of Molecular and Cellular Biology, University of Leeds, Woodhouse Lane,
Leeds LS2 9JT, UK
e School of Chemistry, University of Bristol, Cantock’s Close, Bristol BS8 1TS, UK
f BrisSynBio, University of Bristol, Life Sciences Building, Tyndall Avenue,
Bristol BS8 1TQ, UK
† Electronic supplementary information (ESI) available. See DOI: 10.1039/
d1cb00137j
‡ Authors contributed equally to this work.
Received 26th June 2021,































































































RSC Chem. Biol. © 2021 The Author(s). Published by the Royal Society of Chemistry
interest to 16 of the proteinogenic amino acids (i.e., standard
residues except Ala, Gly, Pro and Cys) and calculates the
difference in binding free energy (DDG) relative to the native
sequence (Fig. 1a). To do this, we adapted BUDE alanine
scanning20,31 to allow variation to different amino acids
(see ESI†). The soft nature of the BUDE forcefield avoids
penalising small geometric overlaps in the modelled structures
and this is key to the speed of these methods, unlike the
Rosetta forcefield, where extensive sampling is required.20 To
establish the PreSaVS workflow, it was applied to both a helix-
and b strand-mediated PPIs (Fig. 1b–i). A modified mNOXA-B/
hMCL-132,33 interaction (referred to as NOXA75–93/MCL-1) was
selected as the model a-helix-mediated PPI (Fig. 1b). NOXA and
MCL-1 are proteins of the B-cell Lymphoma 2 (BCL-2) family of
apoptosis regulators,34 and have been the focus of oncology
drug-discovery efforts.35 The interaction between the SIM pep-
tide found in the M-IR2 region of RanBP2, and hSUMO1
(referred to as SIM2705–2717/SUMO)
36 was chosen as the model
b strand-mediated PPI (Fig. 1f). Small ubiquitin-like modifiers
(SUMO) regulate many cellular processes through their inter-
action with SUMO-interacting motifs (SIMs) within other pro-
teins, and are the subject of ongoing investigation.37
By analogy to hot residues (DDG Z 4.5 kJ mol1), we set
DDG Z 4.5 kJ mol1 13,14 as a threshold for experimental
analyses. The two PPIs were subjected to PreSaVS and the
outcomes visually inspected (Fig. 1d and h; full data in ESI,†
Tables S1 and S2). Based on prediction of a favourable increase
in affinity, we selected NOXA75–93 peptides with substitutions at
L78 and V85 (both hot residues, Fig. 1b and e) for experimental
analyses, specifically focussing on Trp and Phe variants. For
L78, we also selected the Tyr variant as a negative control.
Predictions for SIM2705–2717 identified hot and non-hot resi-
dues, focussing predominantly on substitution of hydrophobic
for charged amino acids (Fig. 1f–i): I2708D, V2710I (hot resi-
due), I2711E and V2713E (hot residue) variations were selected
for experimental validation.
Peptide variants were prepared as N-terminal acetamides
and C-terminal amides (see ESI†). These were tested in fluores-
cence anisotropy (FA) competition assays using a fluorescein-
labelled BIM75–85 peptide (FITC-Ahx-BIM75–85, Kd = 204  16 nM)
or SIM2705–2717 (FITC-peg-SIM2705–2712, Kd = 1.5  0.2 mM)
peptides described previously (see ESI† for sequences and
direct titration data, Fig. S1).20 Competition FA revealed that
NOXA75–93L78F and NOXA75–93L78W variations were tolerated,
whilst the NOXA75–93V85F variant displayed weaker inhibitory
activity (Fig. 2a). As predicted by PreSaVS, the NOXA75–93L78Y
variant was a poor inhibitor providing confidence in the pre-
dictions. The NOXA75–93 peptide binds MCL-1 selectively over
other BCL-2 family members,38 and peptide variants retained
this selectivity in a FA competition assay against a further BCL-
2 family member protein, BCL-xL (Fig. S2, ESI†). Isothermal
calorimetry (ITC) experiments showed comparable Kd values for
the variant peptides relative to NOXA75–93, confirming these
results; variant peptides exhibited a lower entropy and com-
pensatory decrease in enthalpy of binding compared to
NOXA75–93 (Fig. 2b, Table 1 and Fig. S3, ESI†). Lastly, structural
effects of these variations were investigated using circular
dichroism (CD) spectroscopy (Fig. S4, ESI†). The peptides
Fig. 1 PreSaVS applied to NOXA75–93/MCL-1 and SIM2705–2717/SUMO. (a) Schematic depicting workflow; (b) lowest energy NMR-derived structure (PDB
ID: 2JM6) of mNOXA68–93 (cyan)/mMCL-1 (green, hot residues in red); (c) BudeAlaScan and experimental data for NOXA75–93/MCL-1; (d) key PreSaVS
results for NOXA75–93; (e) NOXA75–93 sequences selected for experimental analyses; (f) lowest energy NMR derived structure (PDB ID: 2LAS) of
SIM2705–2717 (cyan)/SUMO (green, hot residues in red); (g) BudeAlaScan and experimental data for SIM2705–2717/SUMO; (h) key PreSaVS results for
SIM2705–2717; (i) SIM2705–2717 sequences selected for experimental analyses.

























































































© 2021 The Author(s). Published by the Royal Society of Chemistry RSC Chem. Biol.
exhibited CD spectra consistent with predominance of random
coil in buffer (peptides exhibited increased helicity in 30%
trifluoroethanol, Fig S5, ESI†).45 The sequence-driven variation
in helicity is greater than the variation in affinity (see Fig. S6,
ESI†) although both are small supporting the hypothesis
that side chain interactions dominate the observed effects of
variation as opposed to a significant change in conformational
preference.
For SIM2705–2717 peptide variants (Fig. 3a and Table 2),
similar inhibitory potency was observed for SIM2705–2717
I2708D (IC50 = 14.8  0.7 mM) in comparison to SIM2705–2717
(IC50 = 21.9  0.3 mM). In the bound state, the hydrophobic I2708
SIM side chain lies proximal to K45 and K46 of SUMO; swapping
this position for Asp may introduce hydrogen-bonding interac-
tions (Fig. 3b). Less surprising was the more conservative
SIM2705–2717V2710I variant peptide, which maintained SUMO
binding with an IC50 = 16.2  1.6 mM. (Fig. 3a). Finally, the
SIM2705–2717I2711E and SIM2705–2717V2713E variants lost inhibi-
tory potency. In the NMR ensemble, I2711 rests against the
surface of the SUMO protein between the hydrophobic Y21 and
the charged K37 residues of (Fig. 3b), implying any benefit from
introduction of a salt bridge may be countered by repulsion from
the electron-rich aromatic ring. Lastly, the V2713 side chain is
solvent exposed (Fig. 3b), so the weaker inhibitory potency of the
V2713E variant cannot be reconciled by considering potential
interactions it may make with the SUMO interface. Alanine
scanning, however, previously showed loss in binding for
V2713A.20 Valine favours b structure,39 and we attribute the loss
of affinity observed for V2713E to a critical structure imposing role
for V2713 in adopting a compliant SUMO-binding conformation.
CD spectra on SIM peptides were consistent with a random coil
conformation as expected (not shown).
An advantage of PreSaVS lies in the ability to identify
tolerated variants – in terms of target binding affinity – with
more desirable physicochemical properties (Table S3 for calcu-
lated physicochemical properties, ESI†). Notable changes were
observed in proteolysis studies. Both NOXA75–93 variants tested
(L78F and L78Y) exhibited E10-fold increased rate of cleavage
by a-chymotrypsin relative to NOXA75–93 (Fig. S7a, ESI†). In
contrast, SIM variants showed improved Proteinase K stability
over SIM2705–2717 (Fig S7b, ESI†), with the greatest protection
observed for the V2713E variant (E9-fold decreased proteolysis
rate). For NOXA75–93, while the peptide bond between residues
L78 (P1) and R79 (P10) is a substrate for a-chymotrypsin,
cleavage susceptibility for peptides containing Leu, Phe, or
Tyr at the P1 position is similar.40 Although small, the
increased helical propensity of NOXA75–93 (Fig. S4 and S5, ESI†)
may contribute to its higher protease resistance compared to the
variant sequences. The broad-range specificity of Proteinase K,40
renders most peptide bonds in the SIM2705–2717 sequence targets
for this protease. The relative Proteinase K resistance of these
peptides (SIM2705–2717 B I2708D B V2710I o I2711E o V2713E)
is similar to their relative affinity for SUMO. This may arise from
subtle changes in protease recognition specificity, although
given proteases recognise substrates in an extended, b-like
conformation as is the case for the SIM2705–2717/SUMO inter-
action, secondary structure propensity may also play a role.
Fig. 2 FA competition and ITC data for NOXA75–93 and variant sequences.
(a) Competition FA (50 mM Tris, 150 mM NaCl, pH 7.5, using 25 nM tracer
and 150 nM MCL-1). (b) ITC data (50 mM Tris, 150 mM NaCl, pH 7.5, 150 mM
peptide).
Table 1 MCL-1 binding parameters and helicities for NOXA75–93 peptides
a
NOXA75–93 L78F L78W L78Y V85F
Kd (mM) 0.4  0.1 1.7  0.1 2.4  0.8 — 0.8  0.1
IC50 (mM) 1.2  0.1 2.7  0.1 2.2  0.1 4100 420
DGb 8.71 7.88 7.66 — 8.35
DHb 19.2  1.5 17.3  3.2 13.1  3.9 — 15.3  3.4
TDSb 12.2 9.44 5.48 — 6.90
% helicityc 15 8 12 — 9
a Determined using conditions as noted in Fig. 2. b (kJ mol1).
c In buffer.
Fig. 3 FA competition data and structural analysis for SIM2705–2717 and
variant sequences; (a) competition FA (50 mM Tris, 150 mM NaCl, 25 nM
tracer, 100 nM SUMO; (b) SIM2705–2717/SUMO (PDB ID: 2LAS) variant
residues highlighted in red showing I2708 proximity to SUMO K45 and
K46 residues, I2711 proximity to SUMO residues Y21 and K37 and V2713
pointing towards solvent.
Table 2 SUMO binding parameters for SIM2705–2717 variant peptides
a
SIM2705–2717 I2708D V2710I I2711E V2713E
IC50 (mM) 21.9  0.3 14.8  0.7 16.1  1.6 4200 4200
a Determined using conditions as noted in Fig. 3.
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Conclusions
We have developed in silico Predictive Saturation Variation
Scanning (PreSaVS) and tested it on a helix- and b strand-
mediated PPIs. Variants of NOXA75–93 and SIM2705–2717 peptides
generated by PreSaVS retained inhibitory potency/affinity for
MCL-1 and SUMO, respectively. Tolerated modifications could
be made at hot and non-hot residues. Further experiments
revealed changes in proteolysis rates of the peptides as a
consequence of the sequence variation. Whereas suppressed
proteolysis is often desired, accelerated proteolysis can be
advantageous for fast-acting peptides.41 This validates PreSaVS
as a fast predictive tool for sequence variation and further
extends the capabilities of the Bristol University Docking
Engine (BUDE).42 We expect the approach to be useful for other
topologies e.g. loops, and, whilst NOXA and SIM are intrinsi-
cally disordered their PPIs are well defined; thus utility of the
approach for ‘‘fuzzy’’ interactions remains to be explored.
Ongoing studies are focussed on exploring the scope to identify
affinity enhancing and/or selectivity modifying variations
across a broader array of PPI targets.43
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